Using malignant cells obtained from 43 NSCLC patients receiving gemcitabine-based chemotherapy, Seve et al (2005) applied immunohistochemical methods to assess the abundance of proteins involved in gemcitabine pathways, including cN-II, one of the cytosolic nucleotidases that have been shown to be predictive factors in patients with acute myeloid leukaemia (AML) receiving cytarabine. Here, NT5C2 is linked to acute myeloid leukemia.